BIOTHERYX

BioTheryX focuses on the development of therapies for hematological malignancies. It intends to leverage its extensive experience and proven commercial success to deliver efficacious therapies to patients with unmet medical needs more quickly and less expensively than the biomedical industry traditionally can and does. To do so, they are exploiting enhanced biology-driven models to identify effective core molecules that can be rapidly exploited using focused and prioritized chemistry approaches coupled with clinically proven translational approaches targeted for cancer and immune dysfunction. The company was founded in 2007 and is headquartered in Chappaqua, New York.